Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors

References

• Hayashi, T., Hideshima, T. and Anderson, K.C. (2003) "Novel therapies for multiple myeloma", Br. J. Haematol., 120, 10–17.
   Web of Science ®Google Scholar
• Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", N. Engl. J. Med., 341, 1565–1571.
   Google Scholar
• Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., et al. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identi-fication of prognostic factors in a phase 2 study of 169 patients", Blood, 98, 492–494.
   Google Scholar
• Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. and Malm, C. (2001) "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma", Br. J. Haematol., 109, 89–96.
   Web of Science ®Google Scholar
• Yakoub-Agha, I., Attal, M., Dumontet, C., Delannoy, V., Moreau, P., Berthou, C., et al. (2002) "Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the intergroupe francophone du myelome (IFM)", Hematol. J., 3, 185 — 192.
   Google Scholar
• Weber, D., Rankin, K., Gavino, M., Delasalle, K. and Alexanian, R. (2003) "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma", J. Clin. Oncol., 21, 16 — 19.
   Web of Science ®Google Scholar
• Schey, S.A., Cavenagh, J., Johnson, R., Child, J.A., Oakervee, H. and Jones, R.W. (2003) "A UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment", Leuk. Res., 27, 909–914.
   Google Scholar
• Dimopoulos, M.A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., et al. (2001) "Thalidomide and dexamethasone combination for refractory multiple myeloma", Ann. Oncol., 12, 991 — 995.
   Google Scholar
• Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., et al. (2001) "Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma", Haematologi-ca, 86, 399 — 403.
   Google Scholar
• Anagnostopoulos, A., Weber, D., Rankin, K., Delasalle, K. and Alexanian, R. (2003) "Thalidomide and dexamethasone for resistant multiple myeloma", Br. J. Haematol., 121, 768–877.
   Web of Science ®Google Scholar
• Moehler, TM., Neben, K., Benner, A., Egerer, G., Krasniqi, F., Ho, AD., et al. (2001) "Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy", Blood, 98, 3846— 3848.
   Google Scholar
• Garcia-Sanz, R., Gonzalez-Fraile, MI., Sierra, M., Lopez, C., Gonzalez, M. and San Miguel, J.F. (2002) "The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma", Hematol. J., 3, 43–48.
   Google Scholar
• Mileshkin, L.R., Biagi, J.J., Mitchell, P., Underhill, C., Grigg, A., Bell, R., et al. (2003) "A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple myeloma reveals an adverse prognostic impact of advanced age", Blood, 13, 13.
   Google Scholar
• Coleman, M., Leonard, J., Lyons, L., Pekle, K., Nahum, K., Pearse, R., et al. (2002) "BLT-D (Clarithromycin [Biaxin], Low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's Macroglobulinemia", Leukemia and Lympho-ma, 43, 1777 — 1782.
   Google Scholar
• Dimopoulos, MA., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., et al. (2004) "Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma", The Hematology Journal, 5, 112 — 117.
   Google Scholar
• Greipp, P.R., San Miguel, J.F., Fonseca, R., et al. (2003) "Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group", Hematol. J., 4\(suppl 1), S42.
   Google Scholar
• Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., et al. (1998) "Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant", Br. J. Haematol., 102, 1115–1123.
   Google Scholar
• Cox, D. (1972) "Regression models and life tables", J. R. Stat. SOC., 43, 187–220.
   Google Scholar
• Richardson, PG., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., et al. (2002) "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma", Blood, 100, 3063–3067.
   PubMed Web of Science ®Google Scholar
• Richardson, P., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. (2003) "A phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma", N. Engl. J. Med., 348, 2609 — 2617.
   Google Scholar
• Dimopoulos, MA., Barlogie, B., Smith, T.L. and Alexanian, R. (1991) "High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma", Ann. Intern. Med., 115, 931 — 935.
   Web of Science ®Google Scholar
• Barlogie, B., Smallwood, L., Smith, T. and Alexanian, R. (1989) "High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma", Ann. Intern. Med., 110, 521–525.
   Web of Science ®Google Scholar